When is vasopressin indicated in adult patients, what are the recommended dosing regimens for vasodilatory shock and central diabetes insipidus, how should therapy be monitored, what are its contraindications, and what alternative agents can be used?

Vasopressin in Adult Patients

Vasopressin should be added to norepinephrine at 0.03 units/minute (not as monotherapy) in adults with vasodilatory shock who remain hypotensive despite adequate fluid resuscitation and first-line norepinephrine therapy. This is the primary indication supported by the Surviving Sepsis Campaign guidelines and FDA approval 1, 2.

Primary Indications

Vasodilatory Shock (Septic Shock and Post-Cardiotomy Shock)

• Septic shock: Add vasopressin 0.01-0.03 units/minute to ongoing norepinephrine infusion when MAP targets (≥65 mmHg) are not achieved with norepinephrine alone 1
• Post-cardiotomy shock: Use 0.03-0.1 units/minute 2
• Never use vasopressin as sole initial vasopressor - norepinephrine remains first-line 1

The rationale: Vasopressin acts through V1a receptors independent of α-adrenergic pathways, which become impaired during metabolic acidosis in shock states. This provides a catecholamine-sparing effect and may reduce norepinephrine requirements 3, 4.

Central Diabetes Insipidus

For acute postoperative central DI, particularly with hypovolemia:

• Dilute vasopressin bolus protocol: 1 unit vasopressin in 1 liter of 0.45% normal saline, given in boluses calculated as (urine output minus 100 mL) 5
• Transition to desmopressin (DDAVP) once hemodynamically stable
• In neonates/infants: Multiple formulations available (buccal, oral tablet, subcutaneous desmopressin) with dosing adjusted for growth and nutrition 6

Recommended Dosing Regimens

For Vasodilatory Shock

Standard dosing algorithm:

1. Start norepinephrine first, titrate to MAP ≥65 mmHg
2. If norepinephrine requirements remain high or MAP target not achieved, add vasopressin at 0.03 units/minute (fixed dose) 1
3. Do not exceed 0.03-0.04 units/minute for routine use 1, 7
4. Doses >0.04 units/minute reserved only for salvage therapy when all other vasopressors have failed 1

Preparation: Dilute 20 units/mL vial with normal saline or D5W to either 0.1 units/mL or 1 unit/mL. Discard unused diluted solution after 18 hours at room temperature or 24 hours refrigerated 2.

The evidence shows vasopressin added to norepinephrine reduces mortality (RR 0.91), reduces atrial fibrillation (RR 0.77), and significantly reduces need for renal replacement therapy, though it increases risk of digital ischemia (RR 2.56) 3.

Monitoring Requirements

Essential monitoring parameters:

• Arterial catheter placement as soon as practical for continuous blood pressure monitoring 1
• MAP target: Maintain ≥65 mmHg 1
• Cardiac output/stroke volume: Monitor in patients not responding to initial therapy 8
• Tissue perfusion markers:
  • Capillary refill time, skin temperature, mottling 8
  • Serial central venous oxygen saturation (ScvO2) if central line present 8
  • Lactate levels 8
• Renal function: Urine output, creatinine, electrolytes (particularly sodium)
• ECG monitoring: Watch for bradycardia, arrhythmias 2
• Peripheral perfusion: Assess digits and skin for ischemia 3

Critical pitfall: Transient diabetes insipidus can occur within 12 hours of vasopressin discontinuation, manifesting as polyuria (>3 L/day), dilute urine, and hypernatremia. This typically self-resolves within 24 hours but requires close monitoring of urine output and serum sodium during and after vasopressin weaning 9.

Contraindications

Absolute contraindications:

• Known allergy or hypersensitivity to vasopressin or chlorobutanol 2

Relative contraindications/cautions:

• Coronary artery disease (risk of myocardial ischemia)
• Peripheral vascular disease (increased digital ischemia risk)
• Pregnancy (may induce uterine contractions) 2
• Chronic kidney disease (though may actually improve renal function in shock states)

Do not use vasopressin for renal protection - this indication is not supported 1.

Alternative Agents

Vasopressor alternatives in order of preference:

1. Norepinephrine: First-line vasopressor (strong recommendation) 1, 10
2. Epinephrine: Add to or substitute for norepinephrine when additional agent needed 1
3. Dopamine: Only in highly selected patients with low tachyarrhythmia risk and absolute/relative bradycardia 1
4. Phenylephrine: Reserved for specific circumstances:
   • Norepinephrine causes serious arrhythmias
   • High cardiac output with persistently low BP
   • Salvage therapy when other agents fail 1

Vasopressin analogues:

• Terlipressin: Longer half-life, but increased peripheral ischemia risk 11
• Selepressin: Pure V1a agonist designed to avoid V2-mediated fluid retention, but recent trials show no superiority over placebo 11

For inotropic support (not vasopressor effect):

• Dobutamine: Up to 20 μg/kg/min for myocardial dysfunction with low cardiac output or persistent hypoperfusion despite adequate MAP and volume 1

Key Clinical Pearls

• Vasopressin works synergistically with catecholamines - effects are additive 2
• Indomethacin may prolong vasopressin effects 2
• The 0.03 units/minute dose is typically fixed, not titrated like catecholamines
• Wean vasopressin when norepinephrine requirements decrease and hemodynamic stability improves
• In less severe shock (lower baseline severity), vasopressin may provide survival benefit beyond just catecholamine-sparing effects 3
• Ensure adequate volume resuscitation before initiating any vasopressor therapy 1, 4